schliessen

Filtern

 

Bibliotheken

Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes

The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth... Full description

Journal Title: International Journal of Cancer 30 July 1992, Vol.51(6), pp.942-948
Main Author: Vaage, Jan
Other Authors: Mayhew, Eric , Lasic, Dan , Martin, Frank
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0020-7136 ; E-ISSN: 1097-0215 ; DOI: 10.1002/ijc.2910510618
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wj10.1002/ijc.2910510618
title: Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
format: Article
creator:
  • Vaage, Jan
  • Mayhew, Eric
  • Lasic, Dan
  • Martin, Frank
subjects:
  • Doxorubicin -- Administration & Dosage
  • Lung Neoplasms -- Secondary
  • Mammary Neoplasms, Experimental -- Drug Therapy
ispartof: International Journal of Cancer, 30 July 1992, Vol.51(6), pp.942-948
description: The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth” liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/ polyethylene glycol‐distearoylphosphatidylethanolamine. The doxorubicin formulations were used to treat recently implanted and well‐established, growing primary mouse mammary carcinomas, and to inhibit the development of spontaneous metastases from intra‐mammary tumor implants. In the treatment of recently implanted primary tumors, the formulations were given in 3 i.v. injections over 15 days, starting 3 or 10 days after tumor implantation. In the treatment of well‐established primary tumors, the mice received 4 i.v. injections over 22 days, starting an average 38 days after tumor implantation. In the preventive treatment against metastases, the formulations were given in 4 i.v. injections over 22 days, starting 22 days or 58 days after primary tumor implantation. The Stealth liposome formulation was significantly more effective than the conventional liposome formulation or the free drug in reducing the incidence of metastases from intra‐mammary implants of tumor MC19 and tumor MC65, in curing mice with recent implants of tumor MC2A, tumor MC2B, and tumor MC65, and in increasing the 8‐week survival of mice with well‐established implants of tumor MC2B. It is concluded that the long circulation time of the Stealth liposome doxorubicin formulation accounts for its superior therapeutic effectiveness. © .
language: eng
source:
identifier: ISSN: 0020-7136 ; E-ISSN: 1097-0215 ; DOI: 10.1002/ijc.2910510618
fulltext: fulltext
issn:
  • 0020-7136
  • 00207136
  • 1097-0215
  • 10970215
url: Link


@attributes
ID896822438
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1002/ijc.2910510618
sourceidwj
recordidTN_wj10.1002/ijc.2910510618
sourcesystemOther
pqid73087515
display
typearticle
titleTherapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
creatorVaage, Jan ; Mayhew, Eric ; Lasic, Dan ; Martin, Frank
ispartofInternational Journal of Cancer, 30 July 1992, Vol.51(6), pp.942-948
identifier
descriptionThe purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth” liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/ polyethylene glycol‐distearoylphosphatidylethanolamine. The doxorubicin formulations were used to treat recently implanted and well‐established, growing primary mouse mammary carcinomas, and to inhibit the development of spontaneous metastases from intra‐mammary tumor implants. In the treatment of recently implanted primary tumors, the formulations were given in 3 i.v. injections over 15 days, starting 3 or 10 days after tumor implantation. In the treatment of well‐established primary tumors, the mice received 4 i.v. injections over 22 days, starting an average 38 days after tumor implantation. In the preventive treatment against metastases, the formulations were given in 4 i.v. injections over 22 days, starting 22 days or 58 days after primary tumor implantation. The Stealth liposome formulation was significantly more effective than the conventional liposome formulation or the free drug in reducing the incidence of metastases from intra‐mammary implants of tumor MC19 and tumor MC65, in curing mice with recent implants of tumor MC2A, tumor MC2B, and tumor MC65, and in increasing the 8‐week survival of mice with well‐established implants of tumor MC2B. It is concluded that the long circulation time of the Stealth liposome doxorubicin formulation accounts for its superior therapeutic effectiveness. © .
languageeng
source
subjectDoxorubicin -- Administration & Dosage ; Lung Neoplasms -- Secondary ; Mammary Neoplasms, Experimental -- Drug Therapy;
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Vaage, Jan
1Mayhew, Eric
2Lasic, Dan
3Martin, Frank
titleTherapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
descriptionThe purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth” liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/ polyethylene glycol‐distearoylphosphatidylethanolamine. The doxorubicin formulations were used to treat recently implanted and well‐established, growing primary mouse mammary carcinomas, and to inhibit the development of spontaneous metastases from intra‐mammary tumor implants. In the treatment of recently implanted primary tumors, the formulations were given in 3 i.v. injections over 15 days, starting 3 or 10 days after tumor implantation. In the treatment of well‐established primary tumors, the mice received 4 i.v. injections over 22 days, starting an average 38 days after tumor implantation. In the preventive treatment against metastases, the formulations were given in 4 i.v. injections over 22 days, starting 22 days or 58 days after primary tumor implantation. The Stealth liposome formulation was significantly more effective than the conventional liposome formulation or the free drug in reducing the incidence of metastases from intra‐mammary implants of tumor MC19 and tumor MC65, in curing mice with recent implants of tumor MC2A, tumor MC2B, and tumor MC65, and in increasing the 8‐week survival of mice with well‐established implants of tumor MC2B. It is concluded that the long circulation time of the Stealth liposome doxorubicin formulation accounts for its superior therapeutic effectiveness. © .
general
0English
1Wiley Subscription Services, Inc., A Wiley Company
210.1002/ijc.2910510618
3Wiley Online Library
sourceidwj
recordidwj10.1002/ijc.2910510618
issn
00020-7136
100207136
21097-0215
310970215
rsrctypearticle
creationdate1992
addtitle
0International Journal of Cancer
1Int. J. Cancer
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[pqid, subject, pages]
sort
titleTherapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
authorVaage, Jan ; Mayhew, Eric ; Lasic, Dan ; Martin, Frank
creationdate19920730
facets
frbrgroupid8884492925740149541
frbrtype5
languageeng
creationdate1992
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontrib
0Vaage, Jan
1Mayhew, Eric
2Lasic, Dan
3Martin, Frank
jtitleInternational Journal of Cancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Vaage
1Mayhew
2Lasic
3Martin
aufirst
0Jan
1Eric
2Dan
3Frank
au
0Vaage, Jan
1Mayhew, Eric
2Lasic, Dan
3Martin, Frank
atitleTherapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
jtitleInternational Journal of Cancer
risdate19920730
volume51
issue6
spage942
epage948
issn0020-7136
eissn1097-0215
genrearticle
ristypeJOUR
abstractThe purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth” liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/ polyethylene glycol‐distearoylphosphatidylethanolamine. The doxorubicin formulations were used to treat recently implanted and well‐established, growing primary mouse mammary carcinomas, and to inhibit the development of spontaneous metastases from intra‐mammary tumor implants. In the treatment of recently implanted primary tumors, the formulations were given in 3 i.v. injections over 15 days, starting 3 or 10 days after tumor implantation. In the treatment of well‐established primary tumors, the mice received 4 i.v. injections over 22 days, starting an average 38 days after tumor implantation. In the preventive treatment against metastases, the formulations were given in 4 i.v. injections over 22 days, starting 22 days or 58 days after primary tumor implantation. The Stealth liposome formulation was significantly more effective than the conventional liposome formulation or the free drug in reducing the incidence of metastases from intra‐mammary implants of tumor MC19 and tumor MC65, in curing mice with recent implants of tumor MC2A, tumor MC2B, and tumor MC65, and in increasing the 8‐week survival of mice with well‐established implants of tumor MC2B. It is concluded that the long circulation time of the Stealth liposome doxorubicin formulation accounts for its superior therapeutic effectiveness. © .
copNew York
pubWiley Subscription Services, Inc., A Wiley Company
doi10.1002/ijc.2910510618
pages942-948
date1992-07-30